# EDGAR Filing Document

**Accession Number:** 0001689739
**File Stem:** 0001493152-25-025639
**Filing Date:** 2025-12
**Character Count:** 11283
**Document Hash:** e2ba61c59c8b8a2a2914f385e7f91478
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-025639.hdr.sgml**: 20251201

**ACCESSION NUMBER**: 0001493152-25-025639

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251201

**DATE AS OF CHANGE**: 20251201

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROVECTUS BIOPHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000315545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900031917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-32172
- **FILM NUMBER:** 251541464

**BUSINESS ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929
- **BUSINESS PHONE:** (866) 594-5999

**MAIL ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROVECTUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAMAGE DIGITAL IMAGING INC
- **DATE OF NAME CHANGE:** 20011126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPM GROUP INC
- **DATE OF NAME CHANGE:** 19920703
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pershing Edward
- **CENTRAL INDEX KEY:** 0001689739

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 2220 SOUTHERLAND AVE
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37919

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**74373P108**

*(CUSIP Number)*

**Heather Raines**<br>800 S. Gay Street, Suite 1610<br>Knoxville TN 37929<br>(866) 594-5999

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/26/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74373P108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pershing Edward** | Name of reporting person<br>**Pershing Edward** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**49093544.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**162350.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**49093544.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**162350.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**49255894.00** | Aggregate amount beneficially owned by each reporting person<br>**49255894.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.56%** | Percent of class represented by amount in Row (11)<br>**10.56%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Sole voting and dispositive power includes 176,000 shares of common stock owned directly by the Reporting Person, 2,822,030 shares of common stock owned by the Reporting Person through a retirement plan, 16,980,144 shares of common stock issuable upon exercise of stock options that are currently exercisable or exercisable within 60 days, 24,324,900 shares of common stock issuable upon conversion of 2,432,490 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, and 4,790,470 shares of common stock issuable upon conversion of 479,047 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $1,371,033 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person.

(2) Shared voting and dispositive power includes 60,600 shares of common stock owned by the Reporting Person's spouse, 16,500 shares of common stock owned by the Reporting Person's spouse through a retirement plan, 3,750 shares of common stock held as custodian for a grandchild, and 81,500 shares of common stock owned by Mr. Pershing's Foundation, a nonprofit corporation of which the Reporting Person is an affiliate.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
PROVECTUS BIOPHARMACEUTICALS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929

This Amendment No. 2 ("Amendment No. 2") amends and supplements the Statement on Schedule 13D filed by Edward Pershing (the "Reporting Person") with the Securities and Exchange Commission (the "SEC") on July 3, 2024 (the "Original Schedule 13D"), as amended by Amendment No. 1 filed with the SEC on December 6, 2024 ("Amendment No. 1," and together with the Original Schedule 13D and this Amendment No. 2, the "Schedule 13D") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Provectus Biopharmaceuticals, Inc. (the "Issuer"). Capitalized terms used herein and not otherwise defined in this Amendment No. 2 shall have the meanings set forth in the Original Schedule 13D. This Amendment No. 2 amends Items 3 and 5(a), (b) and (c), as set forth below.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Paragraph (a) of Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

As of the date of this Amendment No. 2, the Reporting Person beneficially owns an aggregate of 49,255,894 shares of Common Stock, or 10.56% of the Issuer's outstanding shares of Common Stock. The beneficial ownership percentages used in this Schedule 13D are calculated based on a total of 420,279,879 shares of Common Stock outstanding as of November 26, 2025 plus (i) 24,324,900 shares of Common Stock issuable upon conversion of 2,432,490 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person; (ii) 4,790,470 shares of Common Stock issuable upon conversion of 479,047 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $1,371,033 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person; and (iii) 16,980,144 shares of Common Stock issuable upon exercise of stock options that are currently exercisable  or exercisable within 60 days.

**(b)**
Paragraph (b) of Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The Reporting Person has sole voting and dispositive power over (i) 176,000 shares of Common Stock owned directly by the Reporting Person, (ii) 2,822,030 shares of Common Stock owned by the Reporting Person through a retirement plan, (iii) 24,324,900 shares of Common Stock issuable upon conversion of 2,432,490 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, (iv) 4,790,470 shares of Common Stock issuable upon conversion of 479,047 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $1,371,033 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person; and (v) 16,980,144 shares of Common Stock issuable upon exercise of stock options that are currently exercisable  or exercisable within 60 days. The Reporting Person has shared voting and dispositive power over 60,600 shares of Common Stock owned by the Reporting Person's spouse, 16,500 shares of Common Stock owned by the Reporting Person's spouse through a retirement plan, 3,750 shares of Common Stock held as custodian for a grandchild, and 81,500 shares of Common Stock owned by Mr. Pershing's Foundation, a nonprofit corporation of which the Reporting Person is an affiliate.

**(c)**
Paragraph (c) of the Schedule 13D is being amended and supplemented by the addition of the following:

The following transactions were effected during the sixty days prior to Amendment No. 2:

On November 26, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $70,000 pursuant to the Issuer's 2025 Financing.

On November 20, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $30,000 pursuant to the Issuer's 2025 Financing.

On November 13, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $30,000 pursuant to the Issuer's 2025 Financing.

On November 06, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $35,000 pursuant to the Issuer's 2025 Financing.

On October 30, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $65,000 pursuant to the Issuer's 2025 Financing.

On October 23, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $20,000 pursuant to the Issuer's 2025 Financing.

On October 16, 2025, a convertible promissory note in the aggregate principal amount of $50,000 held by the Reporting Person automatically converted into 18,880 shares of the Issuer's Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the convertible note.

On October 10, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $60,000 pursuant to the Issuer's 2025 Financing.

On October 03, 2025, the Reporting Person purchased a convertible promissory note from the Issuer in the principal amount of $35,000 pursuant to the Issuer's 2025 Financing.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pershing Edward

**Signature:** /s/ Edward Pershing

**Name/Title:** Edward Pershing, Chairman and CEO

**Date:** 12/01/2025